AR089812A1 - Agente terapeutico para la diabetes mellitus - Google Patents

Agente terapeutico para la diabetes mellitus

Info

Publication number
AR089812A1
AR089812A1 ARP130100233A ARP130100233A AR089812A1 AR 089812 A1 AR089812 A1 AR 089812A1 AR P130100233 A ARP130100233 A AR P130100233A AR P130100233 A ARP130100233 A AR P130100233A AR 089812 A1 AR089812 A1 AR 089812A1
Authority
AR
Argentina
Prior art keywords
group
therapeutic agent
formula
mellitus diabetes
therapeutic
Prior art date
Application number
ARP130100233A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of AR089812A1 publication Critical patent/AR089812A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un agente terapéutico o profiláctico para enfermedades causadas por trastornos del metabolismo de la glucosa que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, (en la fórmula, en la cual R¹ representa un grupo alcoxi C₁₋₈, un grupo morfolino, un grupo 4-metilpiperazin-1-ilo, o un grupo piperidino, R² representa un grupo nitro o un grupo ciano, X representa un grupo carboxilo o un grupo alcoxicarbonilo C₂₋₇, Y representa un átomo de hidrógeno o un grupo alquilo C₁₋₆).
ARP130100233A 2012-01-27 2013-01-25 Agente terapeutico para la diabetes mellitus AR089812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27

Publications (1)

Publication Number Publication Date
AR089812A1 true AR089812A1 (es) 2014-09-17

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100233A AR089812A1 (es) 2012-01-27 2013-01-25 Agente terapeutico para la diabetes mellitus

Country Status (15)

Country Link
US (1) US20150005506A1 (es)
EP (1) EP2808018B1 (es)
JP (1) JP5924699B2 (es)
KR (1) KR20140134266A (es)
CN (1) CN104066430A (es)
AR (1) AR089812A1 (es)
AU (1) AU2013212865A1 (es)
BR (1) BR112014017902A2 (es)
CA (1) CA2862602A1 (es)
HK (1) HK1201209A1 (es)
IN (1) IN2014DN05972A (es)
MX (1) MX2014008484A (es)
RU (1) RU2014134845A (es)
TW (1) TW201334779A (es)
WO (1) WO2013111870A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221041B1 (ko) * 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP2009501795A (ja) * 2005-07-21 2009-01-22 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
DK2266989T3 (en) * 2008-03-31 2015-11-23 C&C Res Lab Heterocyclic derivatives
EP2282736B1 (en) * 2008-04-30 2015-11-11 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
EP2668953A1 (en) * 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
CN102256488A (zh) * 2008-10-19 2011-11-23 理查德·J·约翰逊 伴随代谢失衡慢性肾病的治疗组合物和治疗方法
US20120219536A1 (en) * 2009-08-24 2012-08-30 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
WO2011159745A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
JPWO2011162390A1 (ja) * 2010-06-25 2013-08-22 帝人ファーマ株式会社 徐放性高血圧および腎機能障害治療剤

Also Published As

Publication number Publication date
JP5924699B2 (ja) 2016-05-25
BR112014017902A2 (pt) 2017-08-22
EP2808018A4 (en) 2015-07-15
WO2013111870A1 (ja) 2013-08-01
IN2014DN05972A (es) 2015-06-26
EP2808018B1 (en) 2018-03-14
EP2808018A1 (en) 2014-12-03
CN104066430A (zh) 2014-09-24
KR20140134266A (ko) 2014-11-21
MX2014008484A (es) 2014-10-14
CA2862602A1 (en) 2013-08-01
US20150005506A1 (en) 2015-01-01
RU2014134845A (ru) 2016-03-20
JPWO2013111870A1 (ja) 2015-05-11
TW201334779A (zh) 2013-09-01
AU2013212865A1 (en) 2014-08-14
HK1201209A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
AR089812A1 (es) Agente terapeutico para la diabetes mellitus
AR092661A1 (es) Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1)
AR093093A1 (es) Tratamientos y profilaxis para el sindrome de lisis tumoral
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CR20120448A (es) Compuesto heterocíclico
DOP2006000170A (es) Nuevos derivados de espirocromanona
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
AR088287A1 (es) Agente terapeutico y agente preventivo para la enfermedad desmielinizante
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
AR082022A1 (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Legal Events

Date Code Title Description
FB Suspension of granting procedure